Home
Contact
Careers
Terms and Conditions
Privacy Policy
About Arcturus
RNA Medicines
Technologies
Pipeline
Business Development
Publications
Investor Relations

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

June 27, 2019

Home
Contact
Careers
Terms and Conditions
Privacy Policy
© 2023 Arcturus Therapeutics, Inc.